Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stevanato Group reported second quarter 2026 financial results largely aligned with its guidance, reflecting steady revenue growth and operational improvements across its segments.</li><li>Total revenue grew 8% year-over-year to EUR 302 million, driven primarily by a 9% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, which offset a 2% decline in the Engineering segment.</li><li>Revenue from high-value solutions, which include premium products like biologics and proprietary drug delivery systems, grew 16% and accounted for 45% of total revenue, emphasizing the company’s strategic focus on higher-margin, differentiated offerings.</li></ul>

Stevanato Group reported second quarter 2026 financial results largely aligned with its guidance, reflecting steady revenue growth and operational improvements across its segments.Total revenue grew 8% year-over-year to EUR 302 million, driven primarily by a 9% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, which offset a 2% decline in the Engineering segment.Revenue from high-value solutions, which include premium products like biologics and proprietary drug delivery systems, grew 16% and accounted for 45% of total revenue, emphasizing the company’s strategic focus on higher-margin, differentiated offerings.

Stevanato Group’s Strategic Pivot — Alina, Nexa & Alba Push Drug Delivery Up The Value Chain!

<ul><li>Stevanato Group commenced fiscal 2026 with solid momentum, as reflected in its first quarter results that aligned closely with management’s expectations.</li><li>The company reported a 10% revenue increase at constant currency, reaching EUR 273.6 million, with growth largely driven by its Biopharmaceutical and Diagnostic Solutions (BDS) segment.</li><li>This segment posted a 13% rise in revenue, fueled primarily by strong demand for pre-fillable syringes, which grew over 20% year-over-year, alongside contributions from cartridges and vials.</li></ul>

Stevanato Group commenced fiscal 2026 with solid momentum, as reflected in its first quarter results that aligned closely with management’s expectations.The company reported a 10% revenue increase at constant currency, reaching EUR 273.6 million, with growth largely driven by its Biopharmaceutical and Diagnostic Solutions (BDS) segment.This segment posted a 13% rise in revenue, fueled primarily by strong demand for pre-fillable syringes, which grew over 20% year-over-year, alongside contributions from cartridges and vials.

Stevanato Group Is Not Just A Packaging Story — Here’s Why GLP-1 Matters!

Podcast by Andrew Walker, a PM at Rangeley Capital, Yet Another Value Podcast

Yet Another Value Podcast

Podcast by Andrew Walker, a PM at Rangeley Capital

Yet Another Value Podcast is a new podcast from Andrew Walker, the founder of yetanothervalueblog.substack.com/. We interview top investors and dive deep into stocks and companies they are currently working on and investing in. While nothing on this channel is investing advice and everyone should do their own diligence, our goal is to frequently feature edgy and actionable value and/or event driven ideas. Please see our legal and disclaimer at: https://yetanothervalueblog.substack.com/p/legal-and-disclaimer

<ul><li>Stevenato is a company that provides containment delivery systems for large pharma companies.</li><li>Their customers include major pharmaceutical companies like Eli Lilly, Novo Nordisk, Pfizer, and Moderna.</li><li>The company experienced significant growth during the pandemic due to the demand for their glass vials for vaccines, but is now facing challenges with overbuilding and potential destocking issues.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.</em></p>

Stevenato is a company that provides containment delivery systems for large pharma companies.Their customers include major pharmaceutical companies like Eli Lilly, Novo Nordisk, Pfizer, and Moderna.The company experienced significant growth during the pandemic due to the demand for their glass vials for vaccines, but is now facing challenges with overbuilding and potential destocking issues.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

$STVN: are oral GLP-1s really a death blow? | Aurelian Research's Leo Trudel

<ul><li>Stevanato Group's financial performance for the fiscal year 2025 was characterized by both growth and challenges, highlighting key strategic areas as well as areas needing improvement.</li><li>With a 9% increase in total company revenue at constant-currency rates, driven by the Biopharmaceutical and Diagnostic Solutions (BDS) segment, Stevanato showed strong traction in certain market areas.</li><li>Notably, high-value solutions constituted 46% of total revenue, reflecting the company's strategic focus on premium products, particularly the Nexa syringe, which saw significant demand increases.</li></ul>

Stevanato Group's financial performance for the fiscal year 2025 was characterized by both growth and challenges, highlighting key strategic areas as well as areas needing improvement.With a 9% increase in total company revenue at constant-currency rates, driven by the Biopharmaceutical and Diagnostic Solutions (BDS) segment, Stevanato showed strong traction in certain market areas.Notably, high-value solutions constituted 46% of total revenue, reflecting the company's strategic focus on premium products, particularly the Nexa syringe, which saw significant demand increases.

Stevanato Group: Riding The Biologics Boom—Can Its Injectable Solutions Become The Backbone Of Next-Gen Drug Delivery?

<ul><li>Stevanato Group delivered third quarter 2025 results that reflected strong execution in its core drug containment business alongside continued weakness in the Engineering segment.</li><li>Revenue rose 9% year over year to $303.2 million, supported by 14% growth in the BDS segment that more than offset a 19% decline in Engineering.</li><li>Performance benefited from shipment timing in BDS, with approximately $10 million of product shipments moved into the quarter to meet customer supply chain needs, largely within high-value solutions.</li></ul>

Stevanato Group delivered third quarter 2025 results that reflected strong execution in its core drug containment business alongside continued weakness in the Engineering segment.Revenue rose 9% year over year to $303.2 million, supported by 14% growth in the BDS segment that more than offset a 19% decline in Engineering.Performance benefited from shipment timing in BDS, with approximately $10 million of product shipments moved into the quarter to meet customer supply chain needs, largely within high-value solutions.

Stevanato Group Ramps Fishers & Latina Capacity—The Make-or-Break Efficiency Story for 2026!

Italy

Stevanato Group is a global provider of integrated solutions for drug containment, drug delivery, and diagnostics to the pharmaceutical, biotechnology, and life sciences industries. The company offers a portfolio of products and services, including glass primary packaging (syringes, vials, cartridges), plastic components, drug delivery systems (pen and auto-injectors), and specialized machinery for pharmaceutical manufacturing. Stevanato Group is headquartered in Piombino Dese, Italy, and was founded in 1949.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stevanato Group (STVN US)

Stevanato Group’s Strategic Pivot — Alina, Nexa & Alba Push Drug Delivery Up The Value Chain!

Stevanato Group reported second quarter 2026 financial results largely aligned with its guidance, reflecting steady revenue growth and operational...

Baptista Research

Stevanato Group Is Not Just A Packaging Story — Here’s Why GLP-1 Matters!

Stevanato Group commenced fiscal 2026 with solid momentum, as reflected in its first quarter results that aligned closely with management’s...

Baptista Research

$STVN: are oral GLP-1s really a death blow? | Aurelian Research's Leo Trudel

Stevenato is a company that provides containment delivery systems for large pharma companies. Their customers include major pharmaceutical...

Yet Another Value Podcast

Stevanato Group: Riding The Biologics Boom—Can Its Injectable Solutions Become The Backbone Of Next-Gen Drug Delivery?

Stevanato Group's financial performance for the fiscal year 2025 was characterized by both growth and challenges, highlighting key strategic areas...

Baptista Research

Stevanato Group Ramps Fishers & Latina Capacity—The Make-or-Break Efficiency Story for 2026!

Stevanato Group delivered third quarter 2025 results that reflected strong execution in its core drug containment business alongside continued...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)